PHASE 8 • ORIGINAL SCIENTIFIC VECTOR ILLUSTRATION LIBRARY
Visual Pharmacology & Scientific Learning Library
Original, anatomically and pharmacologically verified SVG diagrams engineered specifically for THE INDIAN PHARMACIST. Every diagram adapts automatically to Light and Dark themes, includes accessible labels and figure captions, and is paired with a complete text explanation.
8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME)
Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.
Scientific & Clinical Explanation:
When a patient swallows a conventional tablet or capsule, the medicine must first undergo disintegration into granules and dissolution into gastrointestinal fluid (Steps 1–2) before un-ionised or carrier-substrate drug molecules cross the enterocyte membrane of the small intestine (Step 3). Absorbed drug enters the mesenteric capillaries and the hepatic portal vein (Step 4), passing directly through the liver where intestinal and hepatic enzymes (such as CYP3A4) may metabolise a fraction of the dose before it ever reaches the general circulation — known as the first-pass effect (Step 5). The surviving fraction (systemic bioavailability, F) enters systemic arterial/venous blood (Step 6), equilibrates between albumin-bound and free unbound drug (Step 7), distributes across capillary beds into peripheral tissues (Step 8), and binds to target receptors, ion channels, or enzymes to elicit its therapeutic effect (Step 9). Concurrently, hepatic Phase I/II enzymes convert lipophilic drug into water-soluble metabolites (Step 10), which are cleared via renal glomerular filtration/tubular secretion into urine or biliary excretion into faeces (Steps 11–12).
Scientific Reference: NCBI Bookshelf (StatPearls: Drug Absorption, Distribution, Metabolism, and Excretion — https://www.ncbi.nlm.nih.gov/books/) & Indian Pharmacopoeia (IP 2022).
8.2 Intestinal Epithelial Drug Absorption Mechanisms & P-gp Efflux
Figure 8.2: Mechanisms of drug transport across the small intestinal brush-border epithelium (enterocytes): (1) Passive transcellular diffusion, (2) Paracellular transport, (3) Facilitated difusión, (4) Carrier-mediated active uptake (PEPT1/OATP), and (5) P-glycoprotein (P-gp) ATP-dependent efflux.
Scientific & Clinical Explanation:
Drug absorption across the gastrointestinal mucosa occurs predominantly in the duodenum and jejunum due to the vast surface area created by mucosal folds, villi, and microvilli (brush border). Un-ionised, moderately lipophilic molecules cross the lipid bilayer via passive transcellular diffusion driven by Fick's First Law of Diffusion. Small hydrophilic drugs may pass through tight junctions (paracellular pathway), while peptidomimetics (such as beta-lactam antibiotics and ACE inhibitors like enalapril) utilise the H+/peptide cotransporter PEPT1. Conversely, the apical efflux pump P-glycoprotein (P-gp / MDR1) actively extrudes substrates (such as digoxin, dabigatran, and cyclosporine) back into the intestinal lumen, working in concert with enterocyte CYP3A4 to limit oral bioavailability.
8.3 Drug Distribution, Plasma Protein Binding & Physiological Barriers (BBB & Placenta)
Figure 8.3: Reversible equilibrium between plasma protein-bound drug (Albumin for acidic drugs; Alpha-1-Acid Glycoprotein for basic drugs) and unbound pharmacologically active drug, alongside physiological barriers and Apparent Volume of Distribution (Vd).
Scientific & Clinical Explanation:
In the vascular compartment, many drugs bind reversibly to plasma proteins — primarily human serum albumin (which binds acidic/anionic drugs such as warfarin, phenytoin, valproate, and NSAIDs) and alpha-1-acid glycoprotein (which binds basic/cationic drugs such as lidocaine, propranolol, and quinidine). Only the unbound (free) fraction (fu) can diffuse across capillary endothelium to reach extravascular tissue receptors or undergo glomerular filtration. Hypoalbuminaemia (in cirrhosis, nephrotic syndrome, or severe malnutrition) or displacement interactions increase the free fraction of highly bound (>90%), narrow-therapeutic-index drugs like phenytoin, necessitating Sheiner-Tozer correction. Distribution into the central nervous system is restricted by the Blood-Brain Barrier (endothelial tight junctions, astrocytic foot processes, and P-gp efflux).
Scientific Reference: NCBI Bookshelf (StatPearls: Volume of Distribution — https://www.ncbi.nlm.nih.gov/books/) & Clinical Pharmacokinetics Compendia.
8.4 Hepatic Drug Metabolism: Hepatocyte CYP450 Phase I, Phase II Conjugation & Prodrug Activation
Figure 8.4: Hepatocyte Phase I functionalisation (Cytochrome P450 microsomal mixed-function oxidase system) and Phase II conjugation reactions, illustrating active metabolite formation, prodrug bioactivation, and clinical CYP inhibition/induction. Note: Extrahepatic metabolism also occurs in intestinal mucosa, plasma esterases, lungs, and kidneys.
Scientific & Clinical Explanation:
Hepatic biotransformation converts lipophilic xenobiotics into polar, ionised, water-soluble derivatives that resist renal tubular reabsorption. Phase I reactions (oxidation, reduction, hydrolysis) mediated by microsomal Cytochrome P450 (CYP3A4/5 ~50%, CYP2D6 ~20%, CYP2C9/2C19 ~20%, CYP1A2) introduce or unmask a polar functional group (-OH, -NH2, -COOH). Phase II reactions conjugate an endogenous hydrophilic moiety — glucuronic acid (via UGT1A1/2B7), sulfate (SULT), acetate (NAT2), or glutathione (GST) — onto the parent drug or Phase I metabolite. While most metabolism inactivates drugs, prodrugs require enzymatic bioactivation (e.g., Enalapril to Enalaprilat via CES1; Clopidogrel to active thiol via CYP2C19; Codeine to Morphine via CYP2D6). Extrahepatic metabolism is equally vital for drugs like remifentanil and esmolol (plasma/red-cell esterases).
Figure 8.5: Renal handling of drugs across the functional nephron: Net Renal Excretion Rate = (Glomerular Filtration + Active Tubular Secretion) − Passive Tubular Reabsorption.
Scientific & Clinical Explanation:
Renal excretion is the primary elimination pathway for water-soluble drugs and polar Phase I/II metabolites. Blood enters the nephron via the renal artery and afferent arteriole into the glomerular capillary tuft. At the glomerulus and Bowman's capsule (1), only unbound drug (fu) with molecular weight <60 kDa undergoes glomerular filtration (GFR ~120 mL/min in healthy adults). In the proximal convoluted tubule (2), Organic Anion Transporters (OAT1/3) and Organic Cation Transporters (OCT2/MATE) actively secrete protein-bound and ionised drugs (such as penicillins, cephalosporins, furosemide, and metformin) into the tubular lumen; probenecid competitively inhibits OAT to prolong penicillin half-life. In the distal tubule and collecting duct (3), un-ionised lipophilic molecules undergo passive reabsorption back into peritubular capillaries. Changing urine pH traps weak acids or weak bases in their ionised state ('ion trapping'): urinary alkalinisation with IV sodium bicarbonate (pH >7.5) ionises weak acids (salicylates, phenobarbital, methotrexate), accelerating urinary elimination.
PLATE-8.6 • Pharmacodynamics & Drug ActionOriginal Vector SVG • Theme-Adaptive
8.6 Pharmacodynamics: Agonists, Antagonists, Dose-Response Curves & Therapeutic Index
Figure 8.6: Pharmacodynamic receptor occupancy, intrinsic activity (alpha), Competitive vs Non-Competitive Antagonism, Potency (EC50) vs Efficacy (Emax), and Therapeutic Index (TI = TD50 / ED50).
Scientific & Clinical Explanation:
Drug-receptor interaction is governed by two independent parameters: Affinity (the strength of reversible drug-receptor binding, inversely proportional to the dissociation constant Kd) and Intrinsic Activity / Efficacy (alpha, the ability of the bound drug-receptor complex to activate downstream signal transduction). A Full Agonist (alpha = 1, e.g., Morphine at mu-opioid receptors, Adrenaline at beta-adrenoceptors) produces maximal response (Emax = 100%). A Partial Agonist (0 < alpha < 1, e.g., Buprenorphine, Aripiprazole, Pindolol) produces submaximal efficacy even at 100% receptor occupancy and acts as a competitive antagonist in the presence of a full agonist. A Competitive Antagonist (alpha = 0, e.g., Atropine, Naloxone, Losartan) binds reversibly to the orthosteric site, shifting the log dose-response curve to the right (increasing apparent EC50) without reducing Emax. A Non-Competitive or Irreversible Antagonist (e.g., Phenoxybenzamine, Aspirin on platelet COX-1, Omeprazole on H+/K+-ATPase) reduces functional receptor density, depressing Emax.
PLATE-8.7 • Biopharmaceutics & Drug DeliveryOriginal Vector SVG • Theme-Adaptive
8.7 Route-Specific Drug Delivery: Bioavailability, Onset & First-Pass Comparison Across 10 Routes
Figure 8.7: Comparative biopharmaceutics across 10 routes of administration: Oral, Sublingual, Buccal, Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Inhalational, Transdermal, Topical, and Rectal.
Scientific & Clinical Explanation:
The route of administration governs the rate and extent of systemic absorption (bioavailability, F), latency to onset of clinical action, and exposure to pre-systemic hepatic first-pass metabolism. Intravenous (IV) injection delivers drug directly into venous blood (F = 100%, immediate onset within 15–60 seconds), bypassing absorption barriers altogether, making it mandatory for emergencies but irreversible once injected. Sublingual (e.g., Glyceryl Trinitrate for acute angina) and Buccal routes drain into the superior vena cava via the internal jugular vein, bypassing portal circulation and hepatic first-pass extraction. Inhalational delivery (e.g., Salbutamol, Budesonide MDI/DPI) achieves rapid local bronchodilation/anti-inflammatory action with minimal systemic exposure (10–20% lung deposition; spacer devices reduce oropharyngeal impaction). Rectal administration partially bypasses first-pass metabolism (~50% via middle/inferior haemorrhoidal veins; superior haemorrhoidal vein drains to portal vein).
Scientific Reference: NCBI Bookshelf (StatPearls: Medication Routes of Administration — https://www.ncbi.nlm.nih.gov/books/) & Indian Pharmacopoeia (IP 2022).
8.8 Pharmacokinetic Plasma Concentration–Time Curve, Half-Life (t1/2), Steady State (Css) & Loading vs Maintenance Dose
Figure 8.8: Plasma Concentration–Time Curve (Cmax, Tmax, AUC, Therapeutic Window) and Multiple-Dose Accumulation to Steady State (Css reached in 4–5 elimination half-lives) vs Loading Dose.
Scientific & Clinical Explanation:
Following a single oral dose, plasma concentration rises as absorption exceeds elimination until reaching peak concentration (Cmax) at time Tmax, where absorption rate equals elimination rate. Thereafter, elimination predominates. The Area Under the Concentration–Time Curve (AUC) is directly proportional to the bioavailable dose and inversely proportional to Total Systemic Clearance (AUC = [F × Dose] / CL). For safe and effective therapy, concentrations must remain above the Minimum Effective Concentration (MEC) and below the Minimum Toxic Concentration (MTC). When administering repeated maintenance doses at fixed intervals, plasma levels accumulate exponentially, reaching ~94%–97% of Steady-State Concentration (Css = Infusion Rate / CL) after 4 to 5 elimination half-lives (t1/2 = [0.693 × Vd] / CL). For long-half-life drugs (e.g., Digoxin, Amiodarone, Azithromycin) or urgent infections (e.g., Colistin, Vancomycin), a Loading Dose (LD = Target Css × Vd / F) rapidly fills the Volume of Distribution.
Scientific Reference: NCBI Bookshelf (StatPearls: Half-Life, Clearance, and Steady State — https://www.ncbi.nlm.nih.gov/books/).
8.9 Antibiotic Mechanisms of Action: Cell-Wall Synthesis, Ribosomal 30S/50S Protein Synthesis, DNA Gyrase & Folate Pathway
Figure 8.9: Mechanisms of action of major antibacterial classes across bacterial cell-wall synthesis, 30S/50S ribosomal protein translation, nucleic acid replication, and folic acid biosynthesis.
Scientific & Clinical Explanation:
Selective toxicity of antibacterial agents relies on targeting structural and biochemical pathways unique to prokaryotic bacteria. (1) Cell-Wall Synthesis Inhibitors: Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) acylate Penicillin-Binding Proteins (PBPs / transpeptidases), blocking peptidoglycan cross-linking, while Vancomycin binds the D-Ala-D-Ala terminus of nascent peptidoglycan precursors. (2) Protein Synthesis Inhibitors target bacterial 70S ribosomes (composed of 30S and 50S subunits, distinct from human 80S ribosomes): Aminoglycosides (bactericidal; cause mRNA misreading at 30S) and Tetracyclines (block aminoacyl-tRNA attachment at 30S A-site); Macrolides, Clindamycin, and Chloramphenicol target the 50S peptidyl transferase/translocation centre, while Linezolid prevents 70S initiation complex formation. (3) Nucleic Acid Inhibitors: Fluoroquinolones inhibit DNA gyrase (topoisomerase II) and topoisomerase IV; Rifampicin inhibits DNA-dependent RNA polymerase (rpoB). (4) Antimetabolites: Sulfamethoxazole inhibits dihydropteroate synthase and Trimethoprim inhibits dihydrofolate reductase in sequential synergistic blockade.
Figure 8.10: Integrated cardiovascular site-of-action map for antihypertensive drug classes: ACE Inhibitors, ARBs, Dihydropyridine vs Non-Dihydropyridine CCBs, Thiazide/Loop/K+-Sparing Diuretics, and Beta-Blockers.
Scientific & Clinical Explanation:
Blood pressure is regulated by Cardiac Output (Heart Rate × Stroke Volume) and Systemic Vascular Resistance (SVR). (1) Renin-Angiotensin-Aldosterone System (RAAS): Juxtaglomerular cells secrete Renin (stimulated by beta-1 adrenoceptors and low renal perfusion), converting hepatic Angiotensinogen to Angiotensin I. Angiotensin-Converting Enzyme (ACE) converts Angiotensin I to Angiotensin II and simultaneously degrades vasodilatory Bradykinin. ACE Inhibitors (Ramipril, Enalapril) block both pathways — lowering Angiotensin II-mediated vasoconstriction and aldosterone secretion while elevating bradykinin (which contributes to vasodilation but can cause dry cough or angioedema). ARBs (Telmisartan, Losartan) selectively block the AT1 receptor without elevating bradykinin. (2) Calcium Channel Blockers: Dihydropyridines (Amlodipine, Cilnidipine) selectively block vascular smooth muscle L-type Cav1.2 channels, reducing SVR. (3) Thiazide/Thiazide-like Diuretics (Chlorthalidone, Indapamide, HCTZ) inhibit distal convoluted tubule Na+/Cl- cotransporter (NCC). Combining an ACEi and an ARB is contraindicated due to hyperkalaemia and acute kidney injury.
Scientific Reference: NCBI Bookshelf (StatPearls: Renin-Angiotensin-Aldosterone System — https://www.ncbi.nlm.nih.gov/books/) & Indian Guidelines on Hypertension (I-GH-IV).
Figure 8.11: Multi-organ mechanisms of antidiabetic drug classes and insulin receptor signalling across liver, kidney proximal tubule, pancreatic beta/alpha cells, gut incretins, and skeletal muscle.
Scientific & Clinical Explanation:
Type 2 Diabetes Mellitus involves progressive pancreatic beta-cell dysfunction, hepatic glucose overproduction, peripheral insulin resistance in skeletal muscle/adipose tissue, decreased incretin effect, and increased renal SGLT2 glucose reabsorption. (1) Metformin (First-line biguanide) activates hepatic AMP-activated protein kinase (AMPK) and inhibits mitochondrial Complex I, suppressing hepatic gluconeogenesis without causing hypoglycaemia or weight gain; it is contraindicated when eGFR < 30 mL/min/1.73m² due to lactic acidosis risk. (2) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin) inhibit Sodium-Glucose Cotransporter-2 in the S1 segment of the renal proximal tubule, promoting glucosuria, natriuresis, and tubuloglomerular feedback (reducing intraglomerular hypertension, slowing CKD progression, and reducing HFrEF/HFpEF hospitalisations). (3) GLP-1 Receptor Agonists (Semaglutide, Liraglutide) and DPP-4 Inhibitors (Sitagliptin, Vildagliptin, Teneligliptin) augment glucose-dependent insulin release and suppress glucagon. (4) Sulfonylureas (Glimepiride, Gliclazide) bind SUR1 on beta-cell K-ATP channels, causing depolarisation, Ca2+ influx, and insulin exocytosis.
Scientific Reference: ICMR Guidelines for Management of Type 2 Diabetes, ADA Standards of Care, & NCBI Bookshelf (https://www.ncbi.nlm.nih.gov/books/).
Figure 8.12: Coagulation cascade and platelet aggregation targets for Warfarin, UFH, LMWH (Enoxaparin), DOACs (Apixaban, Rivaroxaban, Dabigatran), Antiplatelets, and emergency reversal antidotes.
Scientific & Clinical Explanation:
Antithrombotic pharmacotherapy is divided into Antiplatelets (for arterial, platelet-rich white thrombi in ACS/stents/stroke) and Anticoagulants (for venous thromboembolism DVT/PE and atrial fibrillation cardioembolic stroke prophylaxis). (1) Antiplatelets: Low-dose Aspirin (75–150 mg) irreversibly acetylates Ser530 of platelet COX-1 for the entire 7–10 day platelet lifespan, blocking Thromboxane A2 (TXA2) synthesis. Clopidogrel, Prasugrel (irreversible), and Ticagrelor (reversible) block the platelet ADP P2Y12 receptor, preventing GPIIb/IIIa activation. (2) Anticoagulants: Warfarin inhibits hepatic Vitamin K Epoxide Reductase (VKORC1), depleting reduced Vitamin K required for gamma-carboxylation of clotting Factors II, VII, IX, and X (plus anticoagulant Proteins C and S; Factor VII has the shortest half-life ~6 h, while Prothrombin Factor II has ~60 h). Unfractionated Heparin (UFH) binds Antithrombin III to inactivate both Factor Xa and Thrombin (IIa), whereas Low-Molecular-Weight Heparin (Enoxaparin) preferentially inhibits Factor Xa. Direct Oral Anticoagulants (DOACs) directly inhibit Factor Xa (Apixaban, Rivaroxaban, Edoxaban) or Factor IIa (Dabigatran).
